A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Jonathan Welte
Advertisement
With Simon-Kucher & Partners’ life sciences division
Articles by Jonathan Welte
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
3
The Manufacturing Issues That Continue to Contribute to Drug Shortages
4
Bausch + Lomb Appoints Thomas Appio as Interim CEO
5